MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents

Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Info

Publication number
MA56513A
MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
Authority
MA
Morocco
Prior art keywords
parp14
therapy
protein degradation
targeted protein
targeted
Prior art date
Application number
MA056513A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Laurie B Schenkel
Kerren Kalai Swinger
Melissa Marie Vasbinder
Timothy J N Wigle
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of MA56513A publication Critical patent/MA56513A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA056513A 2019-06-19 2020-06-18 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie MA56513A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19

Publications (1)

Publication Number Publication Date
MA56513A true MA56513A (fr) 2022-04-27

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056513A MA56513A (fr) 2019-06-19 2020-06-18 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Country Status (11)

Country Link
US (2) US20220388985A1 (fr)
EP (1) EP3986887A1 (fr)
JP (2) JP2022537349A (fr)
KR (1) KR102993656B1 (fr)
CN (2) CN114206853A (fr)
AU (1) AU2020296063B2 (fr)
BR (1) BR112021025645A2 (fr)
CA (1) CA3142002A1 (fr)
MA (1) MA56513A (fr)
SG (1) SG11202112980TA (fr)
WO (1) WO2020257416A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14
WO2022150667A1 (fr) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Analogues de nimbolide et leurs méthodes d'utilisation
JP2024505228A (ja) * 2021-01-29 2024-02-05 ライボン・セラピューティクス・インコーポレイテッド 炎症性疾患を処置する方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
CN119923391A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN119923394A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (fr) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 Dérivé de quinazolinone et son utilisation médicale
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2890696A1 (fr) * 2012-08-29 2015-07-08 Amgen, Inc. Composés quinazolinones et leurs dérivés
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
EP4119552A1 (fr) * 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Régulation de récepteurs d'antigène chimériques
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14

Also Published As

Publication number Publication date
CN114206853A (zh) 2022-03-18
JP2025102917A (ja) 2025-07-08
EP3986887A1 (fr) 2022-04-27
SG11202112980TA (en) 2021-12-30
WO2020257416A1 (fr) 2020-12-24
BR112021025645A2 (pt) 2022-02-01
JP7844707B2 (ja) 2026-04-13
CN120398840A (zh) 2025-08-01
KR20220024098A (ko) 2022-03-03
CA3142002A1 (fr) 2020-12-24
JP2022537349A (ja) 2022-08-25
AU2020296063A1 (en) 2021-12-23
AU2020296063B2 (en) 2026-01-29
US20260125362A1 (en) 2026-05-07
KR102993656B1 (ko) 2026-07-23
US20220388985A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
IL286462A (en) Protein tyrosine phosphatase inhibitors
EP3710002A4 (fr) Agents de dégradation et dégrons pour dégradation protéique ciblée
MA53921A (fr) Inhibiteurs de protéine tyrosine phosphatase
IL289534A (en) Parp1 inhibitors
SG11202112980TA (en) Targeted protein degradation of parp14 for use in therapy
EP3897631A4 (fr) Dégradation ciblée de protéines
EP3952914A4 (fr) Procédés et compositions pour une dégradation de protéine ciblée
HRP20220269T8 (hr) Heterociklilamino-supstituirani triazoli kao modulatori rho-povezane protein kinaze
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
EP3565846A4 (fr) Agents thérapeutiques protéiques pour le traitement de cellules sénescentes
PL3917626T3 (pl) Dwutrybowy radioznacznik i terapeutyk wiążący psma
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
PL3999119T3 (pl) Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
CL2018001724A1 (es) Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio
EP3886912A4 (fr) Dendrimère pour thérapie et imagerie
DK3532059T3 (da) Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
EA201791937A1 (ru) Противовоспалительные полипептиды
EP4013440A4 (fr) Peptides thérapeutiques
IL292656B1 (en) Adrenoreceptor inhibitors ADRAC2
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL280706A (en) Non-disruptive mitigation of malware attacks
EP3814510A4 (fr) Réparation à médiation par microhomologie de mutations de gène de microduplication
IL288090A (en) Expression of antigen-binding proteins in the nervous system
MA71624A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie